KOVANAZE® Resource Center
FOR DENTAL PRACTICES

Welcome to the KOVANAZE® Dentist Resource Center. Here you will find all the literature, in-office displays, and video resources necessary to incorporate the use of KOVANAZE® into your office. Use these media resources to promote your use of this groundbreaking alternative to your patients and train your team on how to effectively discuss KOVANAZE® in your office.

Instructions for using the KOVANAZE® logo, brand name, or branding images

  • The Consumer Indication and Important Safety Information must be displayed whenever the KOVANAZE® logo, photos, images, or videos appear.
  • The Consumer Indication and Important Safety Information should not be changed in any way. They cannot be abbreviated or altered.

PATIENT-FACING MATERIALS

In-Office Displays
Download and print these display materials for your lobby, entrance, and front desk, as hand-out sheets or countertop displays, to let patients know KOVANAZE® is available and might be an option for their procedure.

Countertop Promotions
[download - 1.5MB - pdf]

Proud Provider Emblem
[download - 146KB - pdf]

KDA_inserts_digital_v4.5

Patient Information

Patient Information Sheet
[download - 693KB - pdf]

KOVANAZE® Important Facts for Consumers Sheet
[download - 204KB - pdf]

KOVANAZE® Indication and Important Safety Information Sheet for Consumers
[download - 143KB - pdf]

RESOURCES FOR DENTISTS

Digital Best Practices
Having an online presence is the best way to generate future patients in today’s digital environment. Use these essential steps to optimize your digital presence.

Best Practices Sheet
[download - 155KB - pdf]

KOVANAZE® Clinical Materials
Download and print these information sheets for your team to inform them about the use, indications, and important safety information about KOVANAZE®. Please also watch the KOVANAZE® Training Video listed below.

KOVANAZE® Administration Sheet
[download - 2.2MB - pdf]

KOVANAZE® Prescribing Information
[download - 104KB - pdf]

KOVANAZE® Instructions for Use
[download - 7.2MB - pdf]

KDA_inserts_digital_v4.5

KOVANAZE® Marketing Graphics
Use these digital graphics files in your newsletters, website, email campaigns, and online and print advertising. These files can be imported into any graphics application.

KOVANAZE® Graphics Package
[download - 2MB - zip]

VIDEO RESOURCES

KOVANAZE® Training Video
Learn the necessary steps and best practices for successful KOVANAZE® administration and use.

[download - medium 720p - mp4]
[download - large 1080p - mp4]

KOVANAZE® Patient Video
Informational video for patients to be used in your reception area, treatment rooms, website, and social media pages.

[download - medium 720p - mp4]
[download - large 1080p - mp4]

Copyright © 2016 St. Renatus. All Rights Reserved.

Important Safety Information

IMPORTANT SAFETY INFORMATION: Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE® is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure, so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE® is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE® administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE® occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert

IMPORTANT SAFETY INFORMATION: Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Use in patients with uncontrolled hypertension or inadequately controlled active thyroid disease of any type is not advised. Allergic or anaphylactic reactions can occur. If an allergic reaction occurs, seek emergency help immediately. KOVANAZE® is contraindicated in patients with a history of allergy to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. Some clinical trial patients experienced an increase in blood pressure, so blood pressure should be monitored. In addition, patients should be carefully monitored for dysphagia. KOVANAZE® is not recommended for use in patients with a history of frequent nose bleeds. Concomitant use of monoamine oxidase inhibitors, nonselective beta adrenergic antagonist, or tricyclic antidepressants may cause hypertension and is not recommended. Discontinue use of oxymetazoline-containing products 24 hours prior to KOVANAZE® administration. Avoid concomitant use of intranasal products. The most common adverse reactions to KOVANAZE® occurring in >10% of patients include a runny nose, nasal congestion, nasal discomfort, sore throat, and watery eyes.

Click here for full Prescribing Information: Package Insert